Innovative pipeline of cancer immunotherapies addressing critical unmet needs
*Ph2 study in planning stages — Ph2 study may be monotherapy and / or combination with CPI
CRC: colorectal carcinoma | NSCLC: non-small cell lung carcinoma | CPI: Checkpoint inhibitor | mBRAF: mutant homolog B of the Rapidly Accelerated Fibrosarcoma | mTP53: mutant tumor protein p53
